Novartis drug is already approved. They are currently focusing on distribution and undertaking other studies to increase market share in the current treatable population. As I understand, Novartis are still interested in having their treatment offered earlier in the treatment process, which may open the door for Veyonda at some point in the future. Looks like a interesting 3rd and 4th quarter for holders.
Ann: Noxopharm Corporate Presentation, page-5
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
